menu
    • menu

    Company profile for Centrexion Therapeutics

    NEW Drugs in Dev: 6
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Centrexion Therapeutics is transforming the treatment of chronic pain by advancing one of the largest, exclusively pain-focused clinical pipelines of novel, non-opioid therapies. We aim to bridge the safety and efficacy gaps in current approaches to chronic pain management.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Centrexion TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    200 State St, Boston, MA 02109
    Telephone
    Telephone
    +617-837-6911
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://centrexion.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Centrexion's knee pain drug fails two PhIII studies
    Centrexion's knee pain drug fails two PhIII studies

    29 Apr 2022

    // Kyle LaHucik ENDPTS

    https://endpts.com/exclusive-centrexions-knee-pain-drug-fails-two-phiii-studies-but-ex-pfizer-ceo-kindlers-biotech-might-still-ask-for-fda-nod/

    Kyle LaHucik ENDPTS
    29 Apr 2022
    Share Share
    With ex-Allergan CEO on board, OcuTerra nabs $35M for eye drops
    With ex-Allergan CEO on board, OcuTerra nabs $35M for eye drops

    10 Nov 2021

    // K. LaHucik FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/ocuterra-snags-35m-for-phase-2-trial-eye-drop-former-allergan-ceo-as-chair

    K. LaHucik FIERCEBIOTECH
    10 Nov 2021
    Share Share
    Centrexion Therapeutics Announces Issuance of U.S. Composition of Matter Patent
    Centrexion Therapeutics Announces Issuance of U.S. Composition of Matter Patent

    03 Dec 2019

    // GLOBE NEWSWIRE

    https://www.globenewswire.com/news-release/2019/12/03/1955486/0/en/Centrexion-Therapeutics-Announces-Issuance-of-U-S-Composition-of-Matter-Patent-for-Lead-Pipeline-Candidate-CNTX-4975.html

    GLOBE NEWSWIRE
    03 Dec 2019
    Share Share
    Kindler's Centrexion restarts IPO bid to fund phase 3 pain trial
    Kindler's Centrexion restarts IPO bid to fund phase 3 pain trial

    20 Sep 2019

    // Nick P. Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/kindler-s-centrexion-restarts-ipo-bid-to-fund-phase-3-pain-trial

    Nick P. Taylor FIERCE BIOTECH
    20 Sep 2019
    Share Share
    Jeff Kindler's Centrexion renews bid to make public debut
    Jeff Kindler's Centrexion renews bid to make public debut

    19 Sep 2019

    // Natalie Grover ENDPOINT NEWS

    https://endpts.com/jeff-kindlers-centrexion-renews-bid-to-make-public-debut/

    Natalie Grover ENDPOINT NEWS
    19 Sep 2019
    Share Share
    Centrexion farms out pain drug to Lilly in deal worth up to $998M
    Centrexion farms out pain drug to Lilly in deal worth up to $998M

    29 May 2019

    // Amirah Al Idrus FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/centrexion-farms-out-pain-med-to-lilly-for-47-5m-and-could-reap-much-more

    Amirah Al Idrus FIERCE BIOTECH
    29 May 2019
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search